New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy

Summary of New Items – Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy

Page last updated: 26 November 2021

From 1 November 2021, rTMS therapy will be listed on the Medicare Benefits Schedule (MBS) under new items 14216, 14217, 14219 and 14220 for the treatment of major depressive disorder.

The Australian Government announced this new listing in the 2021-22 Budget with an investment of $288.5 million over four years, following recommendations of the Medical Services Advisory Committee (MSAC).

Previously, rTMS was not subsidised on the MBS.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has provided guidance on its website for the following:

  • Guidance on the delivery of Medicare funded rTMS services for hospital inpatient treatment and Type C certification requirements.
  • Information on the RANZCP rTMS training course endorsement process and criteria for assessment by the RANZCP Subcommittee for Continuing Professional Development. Further information about rTMS training requirements, including ‘grandparenting criteria’, is provided in the rTMS MBS Online Fact Sheet below.

rTMS Documents

rTMS - Patient factsheet - 25 October 2021PDF version (PDF 219 KB)
Word version (Word 89 KB)
rTMS - MBS Online Fact Sheet - 25 October 2021PDF version (PDF 207 KB)
Word version (Word 90 KB)
rTMS - FAQ - 29 October 2021PDF version (PDF 269 KB)
Word Version (Word 95 KB)
rTMS - MBS Explanatory Note - 29 October 2021PDF version (PDF 212 KB)
Word version (Word 29 KB)
rTMS - MBS Items - 29 October 2021PDF version (PDF 235 KB)
Word version (Word 89 KB)

In this section